The trial is negative and statins are too benign to withhold based on imaging
X post ↗View all ESC 2026 trials
CorCalPreventionOpen Access
Pooled cohort equations versus coronary artery calcium score in primary prevention of atherosclerotic cardiovascular disease
What happened
CAC score statin guidance fails to meet noninferiority versus PCE for MACE.
- HR 0.99
- 95% CI 0.71-1.38
- P=0.045 for noninferiority
- n=5,772
- 2.7% vs 2.7% at 4.2 years
Does this change practice?
What this trial adds
Experts see CorCal as a formally negative trial for coronary calcium-guided statin initiation, but disagree on what the result means in practice given identical event rates and lower-than-expected events.
Published field read
CorCal found identical outcomes whether statins were guided by calcium scoring or by a risk equation, yet the prespecified noninferiority bar was not cleared. Some experts read this as evidence that calcium scoring adds no proven benefit and that statins remain undertreated, while others argue the calcium approach matched outcomes with fewer statin prescriptions and better adherence. The open question is whether the trial was simply underpowered by low event rates or whether the result should discourage routine calcium scoring for statin decisions.
Still open
Questions raised in published commentaryWhether CorCal was simply underpowered because event rates fell well below projections, leaving the noninferiority question genuinely unanswered.
Whether the higher statin adherence seen with calcium-guided prescribing translates to meaningful long-term benefit with longer follow-up.
How these results will influence guideline recommendations on calcium scoring in primary prevention.
Context from published commentary. Source summaries are not a new guideline recommendation.
Who says what
Noninferiority was not met and no RCT shows improved outcomes with CAC-guided statins
X post ↗Neil J. Stone
ContextBonow Professor of Medicine, Northwestern UniversityCorCal confirms that a calcium score outperforms a probabilistic approach for individual patients
Original post ↗Show 5 more perspectivesShow fewer perspectives
Martha Gulati
Results readoutCardiologistNoninferiority was not met due to low event rates but CAC recommended fewer statins
X post ↗Joseph B. Muhlestein
ContextCodirector of cardiovascular research, Intermountain HealthPCE likely gives statins to many patients who do not need them
Original post ↗Jeffrey L. Anderson
ContextCardiologist, Intermountain Health, Salt Lake CityThe core question is whether direct imaging of plaque beats a risk equation for statin selection
Original post ↗Mohammed Al-Qadami
@mohamme76294268“CAC-guided statin allocation produced similar MACE rates to PCE guidance (2.7% vs 2.7%) and improved adherence, but did not meet the prespecified non-inferiority criterion. Shared decision-making remains key.”
X ↗Gunnar · DadStrengthDaily
@dadstrengthday“CorCal reported at ESC today. 5,772 adults, no known heart disease, randomized to base the statin decision on a calcium score or the old risk calculator. Same events either way: 2.7% both arms. The calculator flagged 3x as many, and 23% took the pill. Calcium score: 62%.”
X ↗What should the author answer first?
Upvote a question you would like answered, or open it to join the discussion.
Full evidence
Why the trial, key points, tables, limitations, PICO, abstract, media & sources
Full evidence
Why the trial, key points, tables, limitations, PICO, abstract, media & sources
Why the trial?
Pooled cohort equations misclassify cardiovascular risk in many primary-prevention patients, while coronary artery calcium directly measures disease. CorCal asked whether CAC-guided statin allocation targets treatment better than risk-equation-guided care.
Does statin-initiation guidance based on a coronary artery calcium CT score reduce MACE compared to pooled cohort equations in adults without known ASCVD, diabetes, or prior statin therapy?
View moreView less
Key Points
- To compare statin-initiation guidance based on pooled cohort equations versus coronary artery calcium scoring for the primary prevention of atherosclerotic cardiovascular disease.
- Randomized trial (CorCal Outcomes) involving 5,772 adults without known ASCVD, diabetes, or prior statin therapy (mean age 64 years; 51% women) at Intermountain Health, USA.
- Participants were assigned to statin-initiation guidance directed by pooled cohort equations (PCE) or a coronary artery calcium (CAC) CT score and followed for 4.2 years.
- The primary endpoint of MACE occurred in 2.7% of patients in both groups (HR 0.99, 95% CI 0.71 to 1.38; p=0.045 for noninferiority), failing to meet the noninferiority criterion due to lower-than-expected event rates reducing power.
- PCE-guided patients received a statin recommendation more than three times as often as CAC-guided patients, but CAC-recommended patients demonstrated higher treatment adherence (62% vs 23%).
Evidence details
What drove the result?
| Outcome | CAC | PCE |
|---|---|---|
| MACE (all-cause death, MI, stroke, or revascularisation) | 2.7% | 2.7% |
| Primary composite · HR 0.99 (95% CI 0.71-1.38); noninferiority criterion not met (p=0.045) | ||
| Adherence among patients recommended a statin | 62% | 23% |
| Process outcome · PCE guidance produced statin recommendations more than three times as often, but adherence was higher with CAC | ||
Limitations & tradeoffs
Statistical certainty
Event rates were far lower than expected, reducing power, and the identical 2.7% rates with a wide CI (0.71–1.38) make the comparison inconclusive rather than negative; noninferiority was not demonstrated.
Representation
Conducted within a single US health system, which may limit generalisability.
Design limitations
No safety data are reported in the record.
Structured PICO
Does statin-initiation guidance based on a coronary artery calcium CT score reduce MACE compared to pooled cohort equations in adults without known ASCVD, diabetes, or prior statin therapy?
P
Population
5,772 adults without known ASCVD, diabetes, or prior statin therapy (mean age 64 years; 51% women), followed for 4.2 years.
I
Intervention
Statin-initiation guidance based on a coronary artery calcium (CAC) CT score
C
Comparator
Statin-initiation guidance based on the pooled cohort equations (PCE)
O
Outcome
MACE (composite of all-cause mortality, myocardial infarction, stroke, or arterial revascularisation)composite
Main Result
Hazard Ratio: 0.99 (95% CI 0.71–1.38)
Absolute Event Rate: 2.7% vs 2.7%
p-value: p=0.045 for noninferiority
Limitations
- Lower-than-expected event rates reduced power.
- Lower-than-expected event rates reduced power
Discussion
No takes yet. Share an insight, caveat, or question.
Expert reaction
What experts said about CorCal
ESC Congress 2026
Expert labels are toward CorCal's result, from named public quotes (n=3). As of Aug 31, 2026.
Where experts stand
Experts see CorCal as a formally negative trial for coronary calcium-guided statin initiation, but disagree on what the result means in practice given identical event rates and lower-than-expected events.
CorCal found identical outcomes whether statins were guided by calcium scoring or by a risk equation, yet the prespecified noninferiority bar was not cleared. Some experts read this as evidence that calcium scoring adds no proven benefit and that statins remain undertreated, while others argue the calcium approach matched outcomes with fewer statin prescriptions and better adherence. The open question is whether the trial was simply underpowered by low event rates or whether the result should discourage routine calcium scoring for statin decisions.
Main debate
Does CorCal discredit calcium-guided statin decisions or validate a leaner prescribing strategy?
No RCT case for calcium scoring2
The trial is negative, and statins are benign enough that withholding them based on imaging is not justified by this evidence.vs
Calcium score targets statins better1
Calcium scoring achieved the same outcomes with fewer prescriptions and higher adherence, supporting a more individualized strategy.Not placed3 reporting, watching, or context only
What they’re arguing about
supportiveneutralcautiouscritical
Counts are expert takes we classified by axis. Tap a row to see the takes behind its count.
Still unclear
Whether CorCal was simply underpowered because event rates fell well below projections, leaving the noninferiority question genuinely unanswered. Whether the higher statin adherence seen with calcium-guided prescribing translates to meaningful long-term benefit with longer follow-up. How these results will influence guideline recommendations on calcium scoring in primary prevention.
Key expert perspectives
JLJeffrey L. AndersonCardiologist, Intermountain Health, Salt Lake CityContextAug 31
The core question is whether direct imaging of plaque beats a risk equation for statin selection
Anderson, a trial investigator, described the central hypothesis as whether coronary artery calcium imaging can do a better job selecting patients for statins than risk factor equations. He noted the large difference in prescribing patterns between the two approaches.
The trial is negative and statins are too benign to withhold based on imaging
Hulten argues that CAC proponents called for an RCT, and now that CorCal is negative, they should re-evaluate their reasoning. He emphasizes that statins are a reasonably benign intervention and that most of the population is undertreated for dyslipidemia.
Distilled from their postX post
Noninferiority was not met and no RCT shows improved outcomes with CAC-guided statins
Fonarow highlights that MACE was identical at 2.7% in both arms but the noninferiority criterion was not met. He notes that CAC led to fewer statin recommendations and stresses that no RCT shows improved clinical outcomes from calcium-guided prescribing.
Implication
CAC-guided statin initiation failed to meet noninferiority criteria for MACE compared to PCE guidance due to low event rates, though it resulted in fewer statin recommendations and higher patient adherence.
Abstract
CorCal Outcomes randomised 5,772 adults without known ASCVD, diabetes, or prior statin therapy (mean age 64 years; 51% women) in Intermountain Health, USA, to statin-initiation guidance based on the pooled cohort equations or a coronary artery calcium CT score. The primary endpoint was MACE (all-cause mortality, myocardial infarction, stroke, or arterial revascularisation). After 4.2 years, MACE occurred in 2.7% of patients in both groups (HR 0.99, 95% CI 0.71 to 1.38; p=0.045 for noninferiority), so the noninferiority criterion was not met. PCE-guided patients received a statin recommendation more than three times as often, but CAC-recommended patients were more adherent (62% vs 23%). Lower-than-expected event rates reduced power. Source: ESC Congress 2026 press, 31 August 2026.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Joseph Muhlestein (2026) conducted an RCT in Primary prevention of ASCVD (n=5,772). Coronary artery calcium CT score guidance vs. Pooled cohort equations guidance was evaluated on MACE (all-cause mortality, myocardial infarction, stroke, or arterial revascularisation) (HR 0.99, 95% CI 0.71-1.38, p=0.045 for noninferiority). Statin-initiation guidance using a CAC score did not meet noninferiority compared to pooled cohort equations for MACE (HR 0.99; 95% CI 0.71-1.38; p=0.045 for noninferiority).